Cero Therapeutics Warrants(Cerow) Financials: Working Capital Turnover Compared To Industry Average, Plus Other Key Ratios
Growth Trend (Last 5 Years)
Growth - working capital turnover
This chart shows the historical trend of working capital turnover for CEROW compared to its industry average over the recent years.
Ratio Definition and Interpretation
Name: Working Capital Turnover
Definition: Working capital turnover shows how efficiently the company uses its short-term resources — like cash, inventory, and receivables — to generate sales. Higher turnover means the company squeezes more sales from its working capital. Lower turnover may indicate inefficient inventory, slow collections, or too much short-term capital tied up unnecessarily.
Interpretation:
• In '2021', CEROW's working capital turnover was 0.00, showing how efficiently working capital is deployed. Industry average for Biotechnology: Biological Products (No Diagnostic Substances) in '2021' stood at 0.37.
• In '2022', CEROW's working capital turnover was 0.00, showing how efficiently working capital is deployed. The figure remained stable compared to '2021'. Industry average for Biotechnology: Biological Products (No Diagnostic Substances) in '2022' stood at 0.31. Industry average declined by 0.05 from previous year.
• In '2023', CEROW's working capital turnover was 0.00, showing how efficiently working capital is deployed. The figure remained stable compared to '2022'. Industry average for Biotechnology: Biological Products (No Diagnostic Substances) in '2023' stood at 0.26. Industry average declined by 0.05 from previous year.
Overall, CEROW's working capital turnover has remained generally stable over the past 3 years.
Formula: Working Capital Turnover = Net Sales / Working Capital
Good Range: Ranges 5-20 depending on business.